Treatment Response and Duration of Therapy in Transplant-Ineligible NDMM
Closing out their module on transplant-ineligible NDMM management, expert panelists consider best practices regarding duration of therapy and adjustments to drug regimens.
Selecting the Optimal Therapy for Patients With Transplant-Ineligible NDMM
Comprehensive discussion on the array of treatment regimens available for patients with transplant-ineligible NDMM and how best to sequence therapy.
Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Expert oncologists focus on a final patient case of transplant-ineligible newly diagnosed multiple myeloma and reflect on the treatment armamentarium in this setting.
Transplant-Eligible NDMM: Optimizing Therapy for Efficacy and Tolerability
Before closing out their review of treatment for transplant-eligible multiple myeloma, panelists consider how they might adjust therapy to optimize tolerability or efficacy.
Selecting Induction Therapy for Patients With High-Risk Transplant-Eligible NDMM
Shared insight on the optimal selection of induction therapy for patients with high-risk transplant-eligible newly diagnosed multiple myeloma.
Patient Case 2: High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma
Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists define high-risk disease and how it impacts treatment.
Consolidation and Maintenance Therapy in Transplant-Eligible NDMM
A brief discussion on the use of consolidation therapy to improve patient outcomes following transplant in newly diagnosed multiple myeloma.
Selecting the Optimal Induction Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Expert perspectives on the real-world use of induction therapy and transplant in patients with transplant-eligible newly diagnosed multiple myeloma.
Recent Updates on Treatment Options for Patients With Transplant-Eligible NDMM
Comprehensive insight on induction therapy regimens in transplant-eligible newly diagnosed multiple myeloma based on the GRIFFIN, MASTER, and DETERMINATION clinical studies.
Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
Expert panelists review the case of transplant-eligible newly diagnosed multiple myeloma and consider optimal selection of induction therapy.
Tailoring Initial Treatment for Newly Diagnosed, Transplantation-Eligible Multiple Myeloma
High-dose melphalan (Alkeran) and autologous stem cell transplantation are commonly incorporated into the initial line of therapy for patients newly diagnosed with multiple myeloma.
Dose Intensity for Breast Cancer
Drs. Armstrong and Davidson have nicely reviewed the use of dose-intensive chemotherapy in the treatment of metastatic and high-risk early-stage breast cancer, and we agree with the basic premise of the article-that there are no conclusive data